MY198813A - 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer - Google Patents

8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Info

Publication number
MY198813A
MY198813A MYPI2023000366A MYPI2023000366A MY198813A MY 198813 A MY198813 A MY 198813A MY PI2023000366 A MYPI2023000366 A MY PI2023000366A MY PI2023000366 A MYPI2023000366 A MY PI2023000366A MY 198813 A MY198813 A MY 198813A
Authority
MY
Malaysia
Prior art keywords
quinolin
compounds
imidazo
cancer
propoxy
Prior art date
Application number
MYPI2023000366A
Other languages
English (en)
Inventor
Thomas Anthony Hunt
Andrew John Eatherton
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY198813A publication Critical patent/MY198813A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2023000366A 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer MY198813A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1516504.6A GB201516504D0 (en) 2015-09-17 2015-09-17 Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
MY198813A true MY198813A (en) 2023-09-29

Family

ID=54544418

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2023000366A MY198813A (en) 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
MYPI2018701049A MY195669A (en) 2015-09-17 2016-09-15 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2018701049A MY195669A (en) 2015-09-17 2016-09-15 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer

Country Status (37)

Country Link
US (5) US9856255B2 (enExample)
EP (2) EP3350180B1 (enExample)
JP (1) JP6605130B2 (enExample)
KR (2) KR102028848B1 (enExample)
CN (1) CN108137576B (enExample)
AR (1) AR106053A1 (enExample)
AU (1) AU2016323399B2 (enExample)
BR (1) BR112018004325B1 (enExample)
CA (1) CA2997399C (enExample)
CL (1) CL2018000677A1 (enExample)
CO (1) CO2018002829A2 (enExample)
CR (1) CR20180172A (enExample)
CY (1) CY1124680T1 (enExample)
DK (2) DK3350180T3 (enExample)
DO (1) DOP2018000065A (enExample)
EA (1) EA033284B1 (enExample)
ES (2) ES2920876T3 (enExample)
GB (1) GB201516504D0 (enExample)
HR (1) HRP20210149T1 (enExample)
HU (2) HUE053066T2 (enExample)
IL (1) IL257847B (enExample)
LT (1) LT3350180T (enExample)
MX (1) MX384930B (enExample)
MY (2) MY198813A (enExample)
NI (1) NI201800033A (enExample)
PE (1) PE20181078A1 (enExample)
PH (1) PH12018500532A1 (enExample)
PL (2) PL3683220T3 (enExample)
PT (2) PT3683220T (enExample)
RS (1) RS61435B1 (enExample)
SI (1) SI3350180T1 (enExample)
SM (1) SMT202100071T1 (enExample)
SV (1) SV2018005655A (enExample)
TN (1) TN2018000078A1 (enExample)
TW (2) TWI762109B (enExample)
WO (1) WO2017046216A1 (enExample)
ZA (1) ZA202209171B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
WO2020052688A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
EP4115883A4 (en) 2020-03-04 2024-04-10 Pharos Ibio Co., Ltd. USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, MITIGATING OR TREATING OVARIAN CANCER
CN116194109A (zh) 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
KR102985456B1 (ko) * 2020-09-28 2026-07-01 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 축합 고리 화합물 및 그 제조 및 응용
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022125614A1 (en) * 2020-12-09 2022-06-16 Stingray Therapeutics, Inc. Phosphonates as inhibitors of enpp1 and cdnp
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115304598B (zh) * 2021-08-25 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 一种杂环类化合物及其制备方法和用途
GB202114704D0 (en) 2021-10-14 2021-12-01 Univ Birmingham ATM inhibition
CN118434736A (zh) * 2022-01-26 2024-08-02 正大天晴药业集团股份有限公司 含有肼基的化合物
CN118984706A (zh) * 2022-04-11 2024-11-19 钟卫 一种取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮衍生物的晶型、其盐的晶型、制备方法及应用
CN121038817A (zh) 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
EP4777108A1 (en) 2023-09-13 2026-07-22 AstraZeneca AB Azd1390, or a pharmaceutically acceptable salt thereof, in combination with radiation for use in a method of treatment of a cns tumour
TW202535383A (zh) 2024-03-13 2025-09-16 瑞典商阿斯特捷利康公司 治療方法
WO2026120558A1 (en) 2024-12-06 2026-06-11 Sun Pharma Advanced Research Company Limited Macrocyclic compounds as atm inhibitors

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ240313A (en) 1990-10-22 1994-04-27 Res Corp Technologies Inc Anti-retrovirus compositions containing aryl and heteroaryl derivatives
TW301607B (enExample) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
EP1107759A1 (en) 1998-08-03 2001-06-20 Basf Corporation Pyridinones for the treatment of sexual dysfunction
EP1150955A2 (en) 1999-02-04 2001-11-07 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002303156A1 (en) 2001-03-23 2002-10-08 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
CA2442654A1 (en) 2001-04-10 2002-10-10 Transtech Pharma, Inc. Probes, systems, and methods for drug discovery
WO2002087618A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
EP1270535A3 (de) 2001-06-20 2004-02-18 Clariant GmbH Verfahren zur Herstellung von substituierten aromatischen Verbindungen
JP4082888B2 (ja) 2001-10-17 2008-04-30 広栄化学工業株式会社 ビアリール化合物の製造法
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
WO2004017920A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US7432375B2 (en) 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
JPWO2004080943A1 (ja) 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
WO2004113258A1 (ja) 2003-06-20 2004-12-29 Shionogi & Co., Ltd. 炭素−炭素結合生成反応
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
CA2591399C (en) 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070032522A1 (en) 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
EP1962861A2 (en) 2005-08-26 2008-09-03 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
RU2478387C2 (ru) 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
EP2474323A3 (en) 2008-03-26 2012-10-10 Novartis AG Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
US8791131B2 (en) 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
US20120093917A1 (en) 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MA33332B1 (fr) * 2009-06-04 2012-06-01 Novartis Ag Dérivés de la 1h-imidazo[4,5-c]quinolinone
CN102803259A (zh) * 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012025213A2 (en) 2010-08-23 2012-03-01 Grünenthal GmbH Novel therapeutic compounds
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
AR083267A1 (es) 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
WO2012075253A2 (en) 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions
AR084731A1 (es) 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
JO3003B1 (ar) * 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
WO2012162254A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
AU2012258618B2 (en) 2011-05-26 2017-05-25 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
US9580409B2 (en) 2011-11-07 2017-02-28 Sunovion Pharmaceuticals, Inc. Modulators of opioid receptors and methods of use thereof
WO2013074965A1 (en) 2011-11-16 2013-05-23 Microbiotix, Inc. Aminoalkyl phenol ether inhibitors of influenza a virus
WO2013157018A1 (en) 2012-04-18 2013-10-24 Indian Institute Of Technology Madras A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics
CA2872541A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
CA2985787A1 (en) 2012-06-07 2013-12-12 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
CA2879704A1 (en) 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
JP2016518328A (ja) 2013-03-12 2016-06-23 キュアジェニックス インコーポレイテッド 癌治療のための化合物
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
WO2015073804A2 (en) 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
EP3077393A1 (en) * 2013-12-06 2016-10-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
PL3277681T3 (pl) 2015-04-02 2019-10-31 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
WO2017011323A1 (en) 2015-07-10 2017-01-19 University Of Maryland, Baltimore Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use

Also Published As

Publication number Publication date
CO2018002829A2 (es) 2018-05-31
IL257847B (en) 2020-08-31
CL2018000677A1 (es) 2018-08-17
US9856255B2 (en) 2018-01-02
HRP20210149T1 (hr) 2021-03-19
CA2997399C (en) 2024-02-20
BR112018004325B1 (pt) 2023-10-17
CN108137576A (zh) 2018-06-08
US20210147416A1 (en) 2021-05-20
PT3350180T (pt) 2021-02-08
US20230286981A1 (en) 2023-09-14
WO2017046216A1 (en) 2017-03-23
DK3350180T3 (da) 2021-02-15
BR112018004325A2 (enExample) 2018-10-02
HUE058884T2 (hu) 2022-09-28
AU2016323399A1 (en) 2018-05-10
US20170081325A1 (en) 2017-03-23
PH12018500532A1 (en) 2018-08-29
TWI714631B (zh) 2021-01-01
PL3683220T3 (pl) 2022-08-01
AU2016323399B2 (en) 2019-04-18
KR102469153B1 (ko) 2022-11-22
EP3350180A1 (en) 2018-07-25
TN2018000078A1 (en) 2019-07-08
LT3350180T (lt) 2021-02-25
KR102028848B1 (ko) 2019-10-04
MX384930B (es) 2025-03-14
SV2018005655A (es) 2018-04-27
AR106053A1 (es) 2017-12-06
MX2018003186A (es) 2018-05-17
PT3683220T (pt) 2022-06-24
PL3350180T3 (pl) 2021-05-17
DK3683220T3 (da) 2022-07-04
CA2997399A1 (en) 2017-03-23
US20180141943A1 (en) 2018-05-24
PE20181078A1 (es) 2018-07-05
ES2853924T3 (es) 2021-09-20
KR20190112852A (ko) 2019-10-07
HK1257413A1 (en) 2019-10-18
JP6605130B2 (ja) 2019-11-13
EP3350180B1 (en) 2020-11-11
EP3683220B1 (en) 2022-04-13
CN108137576B (zh) 2020-09-22
TW202124381A (zh) 2021-07-01
US10457679B2 (en) 2019-10-29
RS61435B1 (sr) 2021-03-31
ZA202209171B (en) 2023-11-29
EA033284B1 (ru) 2019-09-30
US10882858B2 (en) 2021-01-05
CY1124680T1 (el) 2022-07-22
MY195669A (en) 2023-02-03
ES2920876T3 (es) 2022-08-11
TW201722946A (zh) 2017-07-01
EA201890650A1 (ru) 2018-10-31
US11613539B2 (en) 2023-03-28
KR20180052724A (ko) 2018-05-18
EP3683220A1 (en) 2020-07-22
SMT202100071T1 (it) 2021-03-15
SI3350180T1 (sl) 2021-03-31
CR20180172A (es) 2018-05-25
TWI762109B (zh) 2022-04-21
NI201800033A (es) 2018-10-18
IL257847A (en) 2018-04-30
HUE053066T2 (hu) 2021-06-28
DOP2018000065A (es) 2018-03-30
JP2018531226A (ja) 2018-10-25
GB201516504D0 (en) 2015-11-04
US20200102302A1 (en) 2020-04-02
HK1255408A1 (zh) 2019-08-16
NZ741661A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12019501350B1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MX378957B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX372624B (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.